Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07401316 · ClinicalTrials.gov registry record · NA
Circulating Tumor DNA in Stage I, II, and III Germ-Cell Tumors
A NA study, sponsored by Indiana University.
- Recruiting
- Registry status
- NA
- Development phase
- 130
- Enrollment target
NCT07401316 is a NA study that is actively recruiting participants, run by Indiana University. The registered enrollment target is 130 participants.
The verdict
NCT07401316, a NA study, is actively recruiting participants, sponsored by Indiana University.
- RECRUITING
- Registry status
- NA
- Development phase
- 130 participants
- Enrollment target
Study Summary
This study will evaluate the utility of ctDNA detection in patients with high-risk stage I, stage II, and stage III germ cell tumor disease to develop a tool for post-treatment cancer cell detection.
Interventions
- DIAGNOSTIC_TEST Whole blood for ctDNA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2026-06-03 |
| Est. Completion | 2032-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07401316
The ClinicalTrials.gov registry entry for NCT07401316 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Whole blood for ctDNA is the first listed.
NCT07401316 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07401316 about?
NCT07401316 is a clinical study titled "Circulating Tumor DNA in Stage I, II, and III Germ-Cell Tumors". This study will evaluate the utility of ctDNA detection in patients with high-risk stage I, stage II, and stage III germ cell tumor disease to develop a tool for post-treatment cancer cell detection.
What is the current status of trial NCT07401316?
This trial is currently recruiting. It is a NA study. The enrollment target is 130 participants. The study started on 2026-06-03. Estimated completion is 2032-12.
What interventions are being tested in trial NCT07401316?
The interventions under investigation include: Whole blood for ctDNA (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07401316?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.